News

C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion.
C3.ai Inc (AI) is winning back investors with a management shake-up that could redefine its future after CEO and founder Tom ...
C3.ai (NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...
C3.ai, Inc. (AI) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of C3.ai's market ...
Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects.
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.
Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...
Jefferies warns of high attrition in TCS following the layoff debacle, while Nasscom posts an impersonal response; Tata Consultancy Services shares continue to tank, falling 25 per cent in six months ...
Huntington Ingalls Industries ( NYSE: HII) shares jumped more than 5% in premarket trading Thursday after the U.S. defense ...
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...
This leader in cloud observability is swiftly moving into the artificial intelligence space, and it's having major success.